Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy

World J Gastroenterol. 2023 Mar 21;29(11):1669-1684. doi: 10.3748/wjg.v29.i11.1669.

Abstract

Since hepatocellular carcinoma (HCC) represents an important cause of mortality and morbidity all over the world. Currently, it is fundamental not only to achieve a curative treatment but also to manage in the best way any possible recurrence. Even if the latest update of the Barcelona Clinic Liver Cancer guidelines for HCC treatment has introduced new locoregional techniques and confirmed others as well-established clinical practices, there is still no consensus about the treatment of recurrent HCC (RHCC). Locoregional treatments and medical therapy represent two of the most widely accepted approaches for disease control, especially in the advanced stage of liver disease. Different medical treatments are now approved, and others are under investigation. On this basis, radiology plays a central role in the diagnosis of RHCC and the assessment of response to locoregional treatments and medical therapy for RHCC. This review summarized the actual clinical practice by underlining the importance of the radiological approach both in the diagnosis and treatment of RHCC.

Keywords: Ablation; Ablation techniques; Carcinoma; Catheter; Hepatocellular; Liver; Medication therapy management; RECIST; Radio frequency ablation.

Publication types

  • Review

MeSH terms

  • Ablation Techniques*
  • Carcinoma, Hepatocellular* / diagnostic imaging
  • Carcinoma, Hepatocellular* / pathology
  • Carcinoma, Hepatocellular* / therapy
  • Humans
  • Immunotherapy
  • Liver Neoplasms* / diagnostic imaging
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / therapy
  • Magnetic Resonance Imaging
  • Medication Therapy Management*
  • Tomography, X-Ray Computed